menu
    • menu
    [{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Santen"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Not Applicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Alcon"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.93000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.93000000000000005,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Alcon Inc"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.93000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.93000000000000005,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Alcon Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Netarsudil

    Menu

    Netarsudil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Alcon Inc

                            Deal Size : $930.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutica...

                            Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...

                            Brand Name : Rocklatan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 22, 2022

                            Lead Product(s) : Netarsudil,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Alcon Inc

                            Deal Size : $930.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Alcon Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutica...

                            Details : Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye di...

                            Brand Name : Rocklatan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : Netarsudil,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Alcon Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Alcon Inc

                            Deal Size : $930.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

                            Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...

                            Brand Name : Rocklatan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 22, 2022

                            Lead Product(s) : Netarsudil,Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Alcon Inc

                            Deal Size : $930.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCR...

                            Details : Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B cl...

                            Brand Name : Rocklatan

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 20, 2022

                            Lead Product(s) : Netarsudil

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Santen Pharmaceutical

                            Deal Size : $168.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several ...

                            Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...

                            Brand Name : Rhopressa

                            Molecule Type : Small molecule

                            Upfront Cash : $88.0 million

                            December 07, 2021

                            Lead Product(s) : Netarsudil

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Santen Pharmaceutical

                            Deal Size : $168.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Skye Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Skye Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting Phar...

                            Details : THC-VHS-NEC (SBI-100) + Rhopressa® (netarsudil) a Rho-Kinase Inhibitor combination , Produces Superior IOP Lowering Activity.THCVHS a synthetic molecule, developed to treat glaucoma.

                            Brand Name : THC-VHS

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 21, 2021

                            Lead Product(s) : 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netarsudil

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Santen Pharmaceutical

                            Deal Size : $149.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Oth...

                            Details : Santen will look after sales, marketing and pricing decisions relating to Rhopressa® and Rocklatan®. Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa® in Japan.

                            Brand Name : Rhopressa

                            Molecule Type : Small molecule

                            Upfront Cash : $50.0 million

                            October 28, 2020

                            Lead Product(s) : Netarsudil

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Santen Pharmaceutical

                            Deal Size : $149.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth